• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Entera Bio Ltd.

    8/9/24 4:12:22 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ENTX alert in real time by email
    S-8 1 zk2431788.htm S-8
    As filed with the Securities and Exchange Commission on August 9, 2024
    Registration No. 333-_____


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM S-8
     
    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
    ———————————
    Entera Bio Ltd.
    (Exact name of registrant as specified in its charter)
     
    State of Israel
    Not Applicable
    (State or other jurisdiction of incorporation or organization)
    (I.R.S. Employer Identification No.)
       
    Kiryat Hadassah
    Minrav Building – Fifth Floor
    Jerusalem, Israel
    (Address of Principal Executive Offices)
     
    9112002
    (Zip Code)
       
    Entera Bio Ltd. 2018 Equity Incentive Plan

    (Full title of the plan)

    Gerald Lieberman
    Director
    19 Old Woods Drive
    Harrison, New York 10528
    (Name, address, including zip code, and telephone number, including area code, of agent for service)


    Copies to:

    Drew M. Altman, Esq.
    Sami B. Ghneim, Esq.
    Greenberg Traurig, P.A.
    333 S.E. 2nd Avenue, Suite 4400
    Miami, Florida 33131
    (305) 579-0500

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:
     
    Large accelerated filer
    ☐
     
    Accelerated filer
    ☐
    Non-accelerated filer
    ☒
     
    Smaller reporting company
    ☒
         
    Emerging growth company
    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


    STATEMENT OF INCORPORATION BY REFERENCE
     
    This Registration Statement is filed by Entera Bio Ltd. (the “Registrant”) for the purpose of registering additional ordinary shares, par value NIS 0.0000769 per share (“Ordinary Shares”), of the Registrant under the Entera Bio Ltd. 2018 Equity Incentive Plan (the “Plan”).
     
    On July 31, 2024, the shareholders of the Registrant approved an amendment to the Plan to increase the number of Ordinary Shares available for issuance under the Plan by a one-time amount equal to 1,788,515 shares, which shares are registered under this Registration Statement.
     
    Pursuant to Instruction E of Form S-8, the contents of the Registrant’s prior registration statement on Form S-8 registering Ordinary Shares under the Plan (File No. 333-227488) (the “Prior Registration Statement”) is hereby incorporated by reference herein, and the information otherwise required by Form S-8 is omitted, except that the provisions contained in Part II of the Prior Registration Statement are modified as set forth in this Registration Statement.
     
    PART II
     
    Item 3.
    Incorporation of Documents by Reference.
     
    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the “Commission”):
     

    (a)
    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 8, 2024, pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);
     

    (b)
    The Registrant’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2024, filed with the Commission on May 10, 2024 and for the quarter ended June 30, 2024, filed with the Commission on August 9, 2024;
     

    (c)
    The Registrant’s Current Reports on Form 8-K filed with the Commission on January 3, 2024 and August 2, 2024; and
     

    (d)
    The Registrant’s Registration Statement on Form 8-A filed with the Commission on June 25, 2018 (File No. 001-38556), in which there is described the terms, rights and provisions applicable to the Ordinary Shares, including any amendment or report filed for the purpose of updating such description, including the description of the Ordinary Shares filed as Exhibit 2.2 to the Registrant’s Annual Report on Form 20-F filed with the Commission on March 18, 2021.
     
    Additionally, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (not including any information furnished under Items 2.02, 7.01 or 9.01 of Form 8-K, which information is not incorporated by reference herein), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated herein by reference and to be a part of the Registration Statement from the date of filing of such documents. Any statement contained in a document incorporated herein by reference will be deemed to be modified or superseded for purposes of the Registration Statement to the extent that a statement contained herein, or in a subsequently filed document incorporated herein by reference, modifies or supersedes the statement. Any statement modified or superseded will not be deemed, except as modified or superseded, to constitute a part of the Registration Statement.


    Item 8.          Exhibits.
     
    The following are the exhibits required by Item 601 of Regulation S-K:
     
    Exhibit No.
     
    Description
    4.1

    Amended and Restated Articles of Association of Entera Bio Ltd. (incorporated by reference to Exhibit 1.1 to the Form 20-F filed with the Commission on March 18, 2021).
     
     
    4.2

    Entera Bio Ltd. 2018 Equity Incentive Plan (incorporated by reference to Exhibit 99 to the Registration Statement on Form S-8 (File No. 333-227488) filed with the Commission on September 24, 2018).
     
     
    5.1*

    Opinion of Herzog Fox & Neeman.
     
     
    23.1*

    Consent of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm.
     
     
    23.2*

    Consent of Herzog Fox & Neeman (included in Exhibit 5.1).
     
     
    24.1*

    Power of Attorney (included on signature pages hereto).
     
     
    107*

    Calculation of Filing Fee Tables

    * Filed herewith.
     

    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jerusalem, State of Israel, on August 9, 2024.
     
     
    ENTERA BIO LTD.
     
           

    By:
    /s/ Miranda Toledano
     
      Name: Miranda Toledano  
      Title: Chief Executive Officer  



    POWER OF ATTORNEY
     
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Miranda Toledano and Dana Yaacov-Garbeli, and each of them any of whom may act without joinder of the other, with full power to act as such person’s true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign this Registration Statement, and any and all amendments thereto (including post-effective amendments), and to file the same, with exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agent or his substitute, may lawfully do or cause to be done by virtue hereof.
     
    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

    Signature
     
    Title
     
    Date
             
    /s/ Miranda Toledano
     
    Chief Executive Officer and Director
    (Principal Executive Officer)
     
    August 9, 2024
    Miranda Toledano
         
             
    /s/ Dana Yaacov-Garbeli         
     
    Chief Financial Officer
    (Principal Financial and Accounting Officer)
     
    August 9, 2024
    Dana Yaacov-Garbeli
         
             
    /s/ Gerald Lieberman          
     
    Chairman of the Board
     
    August 9, 2024
    Gerald Lieberman
           
             
    /s/ Yonatan Malca          
     
    Director
     
    August 9, 2024
    Yonatan Malca
           
             
    /s/ Sean Ellis         
     
    Director
     
    August 9, 2024
    Sean Ellis
           
             
    /s/ Haya Taitel          
     
    Director
     
    August 9, 2024
    Haya Taitel
           
             
    /s/ Gerald M. Ostrov          
     
    Director
     
    August 9, 2024
    Gerald M. Ostrov
           


    Get the next $ENTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ENTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Rubin Steven D

    3 - Entera Bio Ltd. (0001638097) (Issuer)

    2/5/26 4:30:16 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ostrov Gerald M was granted 28,721 units of Ordinary Shares, increasing direct ownership by 61% to 75,657 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    1/2/26 4:27:03 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ellis Sean was granted 25,371 units of Ordinary Shares, increasing direct ownership by 19% to 160,098 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    1/2/26 4:25:09 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

    This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; oral OXM to enter clinic thereafter Industry veteran Steve Rubin joins Entera's board MIAMI and TEL AVIV, Israel, Feb. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), through its wholly owned subsidiary, OPKO Biologics (OPKO

    2/4/26 8:00:00 AM ET
    $ENTX
    $OPK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook

    Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026                   Oral Hypoparathyroidism Tablet Program to Accelerate with Lead Long-Acting PTH Variants Strategic Partnership Discussions Advancing Across Pipeline JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced its expected corporate milestones for the first quarter of 2026. "We expect to achieve three important goals during Q1 2026

    1/21/26 8:30:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation

    FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613 Underscores Entera's mission to democratize anabolic treatment for osteoporosis patients and caregivers globally JERUSALEM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, is thrilled to congratulate the FNIH-ASBMR-SABRE1 team following the Food and Drug Administration (FDA) broad qualification of total hip bone mineral density (BMD) as a validated regulatory endpoint for nov

    12/23/25 8:30:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    SEC Filings

    View All

    Entera Bio Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Entera Bio Ltd. (0001638097) (Filer)

    2/4/26 8:00:37 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Entera Bio Ltd.

    10-Q - Entera Bio Ltd. (0001638097) (Filer)

    11/14/25 4:11:50 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Entera Bio Ltd. (0001638097) (Filer)

    11/14/25 4:06:59 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Toledano Miranda Jayne bought $19,912 worth of Ordinary Shares (11,000 units at $1.81), increasing direct ownership by 3% to 426,575 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    12/30/25 6:01:25 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taitel Haya bought $9,405 worth of Ordinary Shares (9,500 units at $0.99), increasing direct ownership by 37% to 35,115 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    1/16/24 8:00:12 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taitel Haya bought $5,864 worth of Ordinary Shares (7,615 units at $0.77), increasing direct ownership by 42% to 25,615 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    1/11/24 6:14:57 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Entera Bio with a new price target

    B. Riley Securities initiated coverage of Entera Bio with a rating of Buy and set a new price target of $9.00

    6/16/21 6:22:06 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aegis Capital initiated coverage on Entera Bio with a new price target

    Aegis Capital initiated coverage of Entera Bio with a rating of Buy and set a new price target of $12.00

    3/22/21 10:40:44 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maxim Group reiterated coverage on Entera Bio with a new price target

    Maxim Group reiterated coverage of Entera Bio with a rating of Buy and set a new price target of $10.00 from $5.00 previously

    3/11/21 12:09:00 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Leadership Updates

    Live Leadership Updates

    View All

    Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

    JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. "During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. ("OPKO"). EB613 early mechanistic effects on both trabecular and cortical bone compartments data using 3D-Shaper software analysis was selected for oral presentation out of 1,680 abstracts submit

    5/9/25 4:05:00 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

    JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings more than 20 years of metabolic bone disease and women's health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle mana

    5/15/24 8:00:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

    JERUSALEM, June 07, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has appointed Haya Taitel, Head of Sanofi's Global Transplant Franchise as an independent director to the Company's Board of Directors. "We are thrilled that Haya has joined our Board," said Miranda Toledano, Chief Executive Officer of Entera. "With more than 30 years of experience building industry-leading commercial organizations across big pharma and biotech, Haya brings a veteran and unique perspective to Entera's Board of Directors. We believe that Haya's track record shepherd

    6/7/23 7:30:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Financials

    Live finance-specific insights

    View All

    Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

    JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the following corporate updates. Corporate Updates: Achieved FDA Agreement for Pivotal Study of EB613, the World's First Daily Bone Forming Oral PTH Tablet On October 6th, 2022, Entera announced that it had successfully completed its Type C meeting and reached a record agreement with the U.S. Food and Drug Administration (FDA) that a single pivotal Phase 3 placebo-controlled study could support a New Drug Application (NDA)

    11/10/22 4:15:00 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

    Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underwayCompany reschedules conference call and webcast to Wednesday, May 18 at 8:00 AM EDT  BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and operating results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Highlights EB613 Clinical Update: Entera's lead clinical candidate, EB613, an oral formulation of human parathyroid hormone (1-34), o

    5/12/22 8:00:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio to Report First Quarter 2022 Financial Results on May 12

    BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the three months ended March 31, 2022 on Thursday, May 12, 2022 at 8:30 AM EDT. Thursday, May 12, 2022, 8:30 AM EDTDomestic: 877-269-7756International: 201-689-7817Israel: 1809406247Conference ID: 13728252 Webcast: Entera Bio Earnings Webcast A replay of the webcast will be archived on Entera's website for approximately 45 days following the call. About Entera BioEntera is a leader in the development of orally delivered large molecule therapeutics for use in a

    4/28/22 8:00:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

    SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

    11/20/24 1:48:55 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

    SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

    8/20/24 6:01:17 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Entera Bio Ltd. (Amendment)

    SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

    1/16/24 10:45:49 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care